<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37296379</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Role of the immune system in amyotrophic lateral sclerosis. Analysis of the natural killer cells and other circulating lymphocytes in a cohort of ALS patients.</ArticleTitle><Pagination><StartPage>222</StartPage><MedlinePgn>222</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">222</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-023-03255-x</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Neuroinflammation might be involved in the degeneration and progression of Amyotrophic Lateral Sclerosis (ALS). Here, we studied the role of the circulating lymphocytes in ALS, in particular the NK cells. We focused on the relationship between blood lymphocytes, ALS clinical subtype and disease severity.</AbstractText><AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">Blood samples were collected from 92 patients with sporadic ALS, 21 patients with Primary Lateral Sclerosis (PLS) and 37 patients affected by primary progressive multiple sclerosis (PPMS) with inactive plaques. Blood was taken from ALS and controls at the time of diagnosis/referral. Circulating lymphocytes were analyzed by flow cytometry with specific antibodies. Values were expressed as absolute number (n&#xb0;/&#xb5;l) of viable lymphocytes subpopulations in ALS were compared with controls. Multivariable analysis was made using site of onset, gender changes in ALSFRS-R and disease progression rate (calculated as &#x394;FS score).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Age at onset was 65y (58-71) in ALS (spinal 67.4%; bulbar, 32.6%), 57y (48-78) in PLS and 56y (44-68) PPMS. Absolute blood levels of the lymphocytes in the different cohorts were within normal range. Furthermore, while levels of lymphocytes T and B were not different between disease groups, NK cells were increased in the ALS cohort (ALS&#x2009;=&#x2009;236 [158-360] vs. Controls&#x2009;=&#x2009;174[113-240], p&#x2009;&lt;&#x2009;0.001). In ALS, blood levels of NK cells were not related with the main clinical-demographic variables, including the rate of disease progression. Multivariable analysis suggested that male gender and bulbar onset were independently associated with a risk of high blood NK cells levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We show that blood NK cells are selectively increased in ALS, though their level appear unaffected in patients with an estimated rapidly progressing disease. Being of a male gender and with a bulbar onset seems to confer higher susceptibility to have increased NK lymphocytes levels at diagnosis/referral. Our experiments provides a further clear-cut evidence of the role of the NK lymphocytes as a significant player in ALS pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piccoli</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cognitive and Memory Disorders Clinic, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Clinical Research Center, Laboratory of Neurochemistry, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Bella</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>ALS Clinical Research Center, Laboratory of Neurochemistry, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy. vincenzo.labella@unipa.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Clinical Research Center, Laboratory of Neurochemistry, Department of Biomedicine, Neurosciences and Advanced Diagnosis, University of Palermo, via Gaetano La Loggia, 1, Palermo, I-90129, Italy. vincenzo.labella@unipa.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meraviglia</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Central Laboratory of Advanced Diagnosis and Biomedical Research, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Simone</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Laboratory of Advanced Diagnosis and Biomedical Research, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salemi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Clinic, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Central Laboratory of Advanced Diagnosis and Biomedical Research, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spataro</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALS Clinical Research Center, Laboratory of Neurochemistry, AOUP "Paolo Giaccone" University Teaching Hospital and BiND, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Circulating blood lymphocytes</Keyword><Keyword MajorTopicYN="N">Disease progression</Keyword><Keyword MajorTopicYN="N">NK lymphocytes</Keyword></KeywordList><CoiStatement>None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37296379</ArticleId><ArticleId IdType="pmc">PMC10251617</ArticleId><ArticleId IdType="doi">10.1186/s12883-023-03255-x</ArticleId><ArticleId IdType="pii">10.1186/s12883-023-03255-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wyatt-Johnson SK, Brutkiewicz RR. The complexity of Microglial interactions with Innate and Adaptive Immune cells in Alzheimer&#x2019;s Disease. Front Aging Neurosci. 2020;12(November):1&#x2013;10. doi: 10.3389/fnagi.2020.592359.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.592359</ArticleId><ArticleId IdType="pmc">PMC7718034</ArticleId><ArticleId IdType="pubmed">33328972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendeln A-C, Degenhardt K, Kaurani L, et al. innate_memory_microglia_Nat2018. Nature. 2018;556(7701):332&#x2013;8. doi: 10.1038/s41586-018-0023-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0023-4</ArticleId><ArticleId IdType="pmc">PMC6038912</ArticleId><ArticleId IdType="pubmed">29643512</ArticleId></ArticleIdList></Reference><Reference><Citation>Poli A, Kmiecik J, Domingues O, et al. NK cells in Central Nervous System Disorders. J Immunol. 2013;190(11):5355&#x2013;62. doi: 10.4049/jimmunol.1203401.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203401</ArticleId><ArticleId IdType="pubmed">23687193</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al. Pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009&#x2013;23. doi: 10.1016/j.neuron.2014.01.013.Microglia.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013.Microglia</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front Immunol. 2017;8(AUG):1&#x2013;12. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31(5):635&#x2013;9. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;45. doi: 10.1146/annurev.immunol.021908.132528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132528</ArticleId><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084&#x2013;98. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP. Amyotrophic lateral sclerosis. Curr Opin Neurol. 1994;7(4):310&#x2013;5. doi: 10.1097/00019052-199408000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00019052-199408000-00006</ArticleId><ArticleId IdType="pubmed">7952238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet. 2013;83(5):408&#x2013;16. doi: 10.1111/cge.12117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12117</ArticleId><ArticleId IdType="pubmed">23379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771&#x2013;6. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):364&#x2013;75. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-&#x3b2;. J Neuroimmunol. 2009;210(1&#x2013;2):3&#x2013;12. doi: 10.1016/j.jneuroim.2009.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.003</ArticleId><ArticleId IdType="pubmed">19269040</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009;4(4):389&#x2013;98. doi: 10.1007/s11481-009-9171-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-009-9171-5</ArticleId><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011;30(JUNE):4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, Cocozza G, Porzia A, et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of amyotrophic lateral sclerosis. Nat Commun. 2020;11(1). 10.1038/s41467-020-15644-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156729</ArticleId><ArticleId IdType="pubmed">32286313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur K, Chen P-C, Ko M-W, et al. The potential role of cytotoxic Immune Effectors in induction, progression and pathogenesis of amyotrophic lateral sclerosis (ALS) Cells. 2022;11(21):3431. doi: 10.3390/cells11213431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11213431</ArticleId><ArticleId IdType="pmc">PMC9656116</ArticleId><ArticleId IdType="pubmed">36359827</ArticleId></ArticleIdList></Reference><Reference><Citation>La Bella V, Iannitto E, Cuffaro L, Spataro R. A rapidly progressive motor neuron disease associated to a natural killer cells leukaemia. J Neurol Sci. 2019;398(January):117&#x2013;8. doi: 10.1016/j.jns.2019.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.029</ArticleId><ArticleId IdType="pubmed">30708207</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293&#x2013;9. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;7. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Comans-Bitter WM, De Groot R, Van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations. J Pediatr. 1997;130(3):388&#x2013;93. doi: 10.1016/S0022-3476(97)70200-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(97)70200-2</ArticleId><ArticleId IdType="pubmed">9063413</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8. 10.3389/fimmu.2017.01124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5601256</ArticleId><ArticleId IdType="pubmed">28955340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Zhou X, He D, Li Z, Xie X, Ren Y. Reduction of peripheral blood iNKT and &#x3b3;&#x3b4;T cells in patients with Parkinson&#x2019;s Disease: an observational study. Front Immunol. 2020;11(June):1&#x2013;7. doi: 10.3389/fimmu.2020.01329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01329</ArticleId><ArticleId IdType="pmc">PMC7330172</ArticleId><ArticleId IdType="pubmed">32670293</ArticleId></ArticleIdList></Reference><Reference><Citation>Earls RH, Lee JK. The role of natural killer cells in Parkinson&#x2019;s disease. Exp Mol Med. 2020;52(9):1517&#x2013;25. doi: 10.1038/s12276-020-00505-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00505-7</ArticleId><ArticleId IdType="pmc">PMC8080760</ArticleId><ArticleId IdType="pubmed">32973221</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Evangelopoulos E, Sereti E, et al. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand. 2012;125(4):260&#x2013;4. doi: 10.1111/j.1600-0404.2011.01528.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2011.01528.x</ArticleId><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid Amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74(12):1446&#x2013;54. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE. 2017;12(7):1&#x2013;21. doi: 10.1371/journal.pone.0182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Beckers J, Gossye H, Van Damme P. The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Mol Neurodegener. 2022;17(1):22e1&#x2013;e23. doi: 10.1186/s13024-022-00525-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00525-z</ArticleId><ArticleId IdType="pmc">PMC8932121</ArticleId><ArticleId IdType="pubmed">35303907</ArticleId></ArticleIdList></Reference><Reference><Citation>MacCauley ME, O&#x2019;Rourke JG, Yanez A, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585(7823):96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Famie JP, Piecuch CE, et al. NK cells associate with ALS in a sex- and age-dependent manner. JCI Insight. 2021;6(11):147129e1&#x2013;16. doi: 10.1172/jci.insight.147129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147129</ArticleId><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Militello A, Vitello G, Lunetta C, et al. The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. J Neurol Sci. 2002;195(1):67&#x2013;70. doi: 10.1016/S0022-510X(01)00688-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00688-8</ArticleId><ArticleId IdType="pubmed">11867076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xea;ne G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimer&#x2019;s Dement. 2015;11(3):310&#x2013;20. doi: 10.1016/j.jalz.2013.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.10.005</ArticleId><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan KB, Ph D, Weuve J et al. Cognitive impairment in the United States (2020&#x2013;2060). 2022;17(12):1966&#x2013;75. 10.1002/alz.12362.Population</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013315</ArticleId><ArticleId IdType="pubmed">34043283</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SY, Tsai ST. The epidemiology of Parkinson&#x2019;s disease. Tzu Chi Med J. 2010;22(2):73&#x2013;81. doi: 10.1016/S1016-3190(10)60044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1016-3190(10)60044-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuganti R, Sohrabji F. Age and sex differences in post-ischemic outcome and therapy. Neurochem Int. 2019;127. 10.1016/j.neuint.2019.104472</Citation><ArticleIdList><ArticleId IdType="pubmed">31128131</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Piancone F, Tortorella P, et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148(1):79&#x2013;88. doi: 10.1016/j.clim.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.04.010</ArticleId><ArticleId IdType="pubmed">23665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Bracci PM, Azhir A, Forrest BD, McGrath MS. Macrophage-targeted Sodium Chlorite (NP001) slows progression of amyotrophic lateral sclerosis (ALS) through regulation of Microbial translocation. Biomedicines. 2022;10(11):2907. doi: 10.3390/biomedicines10112907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10112907</ArticleId><ArticleId IdType="pmc">PMC9687998</ArticleId><ArticleId IdType="pubmed">36428474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcgill RB, Steyn FJ, Ngo ST, et al. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun. 2020;2(1):1&#x2013;11. doi: 10.1093/braincomms/fcaa013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa013</ArticleId><ArticleId IdType="pmc">PMC7530830</ArticleId><ArticleId IdType="pubmed">33033799</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, et al. Cytotoxic CD8 + T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A. 2019;116(6):2312&#x2013;7. doi: 10.1073/pnas.1815961116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>